It is with great pleasure that we announce the appointment of Dr. Franck Bladou and Dr. Simon Tanguay as the Co-leads for the Genito-urinary Disease Site Team of the Rossy Cancer Network (RCN), effective immediately.

The disease site teams are at the heart of the clinical focus of the RCN. These cross-institutional working groups will tackle a number of joint initiatives, improving outcomes in cancer survival and quality of life.

The Genito-urinary group will concentrate on integrating tumour boards, developing network-wide clinical guidelines, and defining the needs of the RCN IT infrastructure in order to measure treatment outcomes and drive improvement initiatives.

Dr. Bladou graduated from the University of Bordeaux 2 Medical School in France and completed his urology training at the University of the Mediterranean, Marseille. Following a three-year clinical fellowship in Marseilles, he pursued an 18-month research fellowship in prostate cancer at the University of Washington, Seattle.

He was appointed Professor of Urology at the University of the Mediterranean in 1997, where he practiced as a clinical urologic oncologist, while also acting as director of the uro-oncology team for the regional cancer center. In 2007, he went on to become the Head of the Department of Urology at Sainte Marguerite Hospital in Marseille. He joined the team at the Jewish General Hospital in 2011, where he was appointed Chief of the Department of Urology. He is also Professor of Surgery (Urology) and Oncology at McGill University and has held the Herbert Black Chair in Surgical Oncology since 2013.

He has obtained numerous independent peer-reviewed grants, notably from the French Institut National du Cancer and is currently a reviewer for several journals, including European Urology. He has been a member of the board of the European Society of Onco-Urology (ESOU) for almost a decade. His surgical expertise and proctorship are in the field of laparoscopy, robotic surgery and brachytherapy.

Dr. Simon Tanguay obtained his medical degree at the Université de Sherbrooke and completed his urology training at McGill University, before pursuing his fellowship in urologic oncology at the University of Texas: MD Anderson Cancer Center.

Since 1995, Dr. Tanguay has been practicing at the McGill University Health Centre. He is a professor in the Department of Surgery (Division of Urology) at McGill University, as well as Director of the MUHC Urologic Oncology Department and Co-Director of the Urology Clinical Research Unit.
During his career, Dr. Tanguay was actively involved in the Quebec Urological Association, where he served as president of continuing medical education. He was also a member of the executive committee of the Genito-Urinary Group at the National Cancer Institute of Canada. He is currently a member of the Medical Advisory Board for Kidney Cancer Canada and holds the position of general secretary of the Société Internationale d’Urologie (SIU).

The complementary experience of Dr. Bladou and Dr. Tanguay makes them well suited to be the Genito-urinary Disease Site Leads for the Rossy Cancer Network. Please join us in wishing them much success in their new RCN leadership roles.

Sincerely,

Wilson H. Miller, Jr., MD, PhD
Clinical Lead
Rossy Cancer Network